An Incisive, In-depth Analysis on the Oral Controlled Release Drug Delivery Technology Market
This study offers a comprehensive, 360 degree analysis on the Oral Controlled Release Drug Delivery Technology market, bringing to fore insights that can help stakeholders identify the opportunities as well as challenges. It tracks the global Oral Controlled Release Drug Delivery Technology market across key regions, and offers in-depth commentary and accurate quantitative insights. The study also includes incisive competitive landscape analysis, and provides key recommendations to market players on winning imperatives and successful strategies.
Large-scale requirement of anti-hypertensive drugs and higher adoption of combination approaches drive the global oral controlled release drug delivery technology market
The increase in generic drug consumption is driven by rising access to healthcare facilities and is fuelling the need for faster availability of drugs in oral solid dosages. This in turn fuels the need for application of controlled release technology, which could increase the availability of the drugs in reduced dosages. Further, with many big drug makers establishing a local manufacturing presence across various regions, the adoption of controlled release technology is expected to witness a growing spiral in the coming years especially in countries such as Brazil, Argentina, Costa Rica and Mexico.
The combination of various technologies helps in rapidly overcoming problems associated with poorly soluble candidates. This is being aided through greater technology sharing through various conferences and symposiums where companies sharing similar thought processes meet and plan eventual outcomes. This helps in better pricing and rapid time to market for the otherwise unviable products in the short run. A higher adoption of combination approaches is expected to boost the global market for oral controlled release drug delivery technology.
Increasing approvals of modified and extended release oral dosage forms by PMDA is likely to drive the growth in revenue of the Japan oral controlled release drug delivery technology market. In the case of new approvals, high preference towards tablets and capsules has been observed, as formulation scientists find it easy to create formulations for clinical as well as therapeutic use. Moreover, when compared to western countries such as the U.S. and Germany, Japan offers greater variety in the choice of oral solid dosage forms due to increased accessibility to local formulations. Large-scale requirement of anti-hypertensive drugs are likely to boost the market growth to a great extent. The large-scale requirement of anti-hypertensive drugs is fuelling the need for more companies to set up plants deploying controlled release technologies. The requirement is more for technology adoption of OROS and SODAS. Indigenous development of pharmaceutical infrastructure is a very important factor expected to fuel revenue growth of the oral controlled release drug delivery technology market.
Diffusion and Dissolution are the most preferred controlled release systems, representing a lucrative market opportunity for manufacturers of oral controlled release drug delivery technologies
The Dissolution Controlled Release System segment dominated the global oral controlled release drug delivery technology market in terms of revenue in 2017, and the trend is projected to continue throughout the forecast period. Dissolution Controlled Release System is the most attractive segment, with an attractiveness index of 3.6 over the forecast period. This segment accounted for close to 45% value share in 2017 and is projected to hold about 50% share by 2027 end. The Others segment, which includes upcoming technologies such as nanotechnology and other advanced matrix technologies is also growing at an exponential rate in terms of revenue in 2017 and the trend is projected to sustain throughout the forecast period. The Others segment is the most attractive segment, with a market attractiveness index of 0.6 over the forecast period.
Controlled Release Formulations – A common strategy to extend the product life cycle
Controlled Release is the most common strategy adopted by pharma giants across the globe to extend the product life cycle. Modified or controlled release formulations of pre-approved drugs are enjoying extended market exclusivity. The introduction of proprietary prescribed medicines in controlled release forms will help drive revenue growth of the global market. Other release mechanisms include enteric release, such as those used in enteric softgel capsules, osmotically active release, effervescent and sublingual release. OROS (Johnson & Johnson and Alza Corporation) and SODAS (Elan Technologies) are the most commercialised technologies in the oral controlled release drug delivery technology market.
Among all the routes that have been tried and tested for ensuring the accurate and systemic delivery of drugs, oral drug delivery is the most commonly used and trusted method for the administration of various pharmaceutical products. As it enables smooth delivery of drugs with various dosage forms, leading players in the pharmaceuticals industry are focusing on further improving features of oral drug delivery methods.
The demand for oral controlled release drug delivery solutions is growing tremendously owing to its benefits in delivering a drug in a skillful, measured, and controlled manner so as to ensure maximum adherence to the prescribed medication. Leading players in the oral controlled release drug delivery market are further experimenting with innovative drug release systems such as dissolution and diffusion controlled release systems and osmotically controlled release systems, to enhance the efficiency and predictability of their products.
Key players in the global oral controlled release drug delivery technology market are focussing on capacity optimisation and technology partnerships, which ultimately increases contract development and manufacturing activities. Insights like this are the highlight of our new publication titled “Oral Controlled Release Drug Delivery Technology Market: Global Industry Analysis (2012 – 2016) and Opportunity Assessment (2017 – 2027).” While examining this market in detail our analysts have observed that the oral controlled release drug delivery technology industry has a limited time of approximately five years to facilitate effectiveness of technology for sustenance. Industry experts have noted that the best strategy to secure more valuable next-generation reformulated products is a meaningful adoption of drug delivery systems through partnerships between pharmaceutical companies and drug delivery companies.
Lack of sufficient investment opportunities in developing regions is keeping the market for oral controlled release drug delivery technologies limited to North America and Western Europe. Further, the launch of new chemical entities (NCE) is fuelling the need to develop innovative technologies at a low cost that can be readily adapted. Scaling up from the batch process is crucial and many times the prime reason for redundancy of technology.
Survey respondents’ inputs form a crucial part of our report
According to the technical support manager of BASF, “Targeted drug delivery, avoiding side effects and avoiding toxicity are key features fuelling the use of adequate polymeric excipients in the design and development of controlled release drugs.”
“International target markets such as Russia, CIS countries, India and China are growing at exponential rates owing to the heavy demand for CR technology,” states the Engineering Manager, Acino International AG.
The R & D Executive of Gattefosse further adds, “Particle engineering techniques such as melt extrusion, melt congealing, and spray atomisation are the biggest accelerators for developing controlled release drug delivery systems.”
Market sizing and forecasting
This report on the oral controlled release drug delivery technology market covers the market for drug delivery systems used to formulate controlled release drugs that are consumed orally. Increasing demand for reduced dosage, higher effectiveness through greater drug transport, higher action time and increased patient compliance to treatment schedules are factors fuelling the need for innovative controlled release technologies. The market size is measured in terms of value (US$) of oral controlled release formulations sold in a particular year. Accordingly, forecast factors have been developed to understand the adoption and growth rate for each of the individual technologies. Interviews have also been conducted with top contract manufacturing organisations to understand the comparative adoption of various technologies across drug classes and the process considerations behind them. Our research includes in-depth secondary research and primary research including discussions with formulation scientists, process engineers, academic professors and physicians. While a top-down approach has been primarily used to assess the market numbers, a bottom-up approach on a country level has been conducted in order to triangulate the values.
By Drug Release System
By Dosage Form
We have adopted a systematic research approach while inspecting this report. In-depth secondary research is used to arrive at the overall market size, top industry players, top products and industry associations. Our analysts have formulated a detailed discussion guide to conduct exhaustive interviews with industry experts, industry players, distributors and retailers. Data is validated using the triangulation method, wherein primary and secondary research data along with Future Market Insights’ analysis contribute to the final data.